

Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1-61. (Cancelled)

62. (Previously presented) A method for treating Tumor Necrosis Factor-alpha ($\text{TNF}\alpha$) mediated immune reaction that causes corneal transplant rejection in a patient, comprising topically administering directly to the eye of said patient an effective amount of anti- $\text{TNF}\alpha$ F(ab')_2 neutralizing antibody fragments.

63. (Previously presented) The method of claim 62, wherein said anti- $\text{TNF}\alpha$ F(ab')_2 neutralizing antibody fragments are polyclonal.

64. (Previously presented) The method of claim 63, wherein said anti- $\text{TNF}\alpha$ F(ab')_2 neutralizing antibody fragments are free of albumin, whole antibodies, pyrogens, and/or viruses.

65. (Previously presented) The method of claim 62, wherein said anti- $\text{TNF}\alpha$ F(ab')_2 neutralizing antibody fragments are administered in combination with a dermatologically or ophthalmically acceptable carrier.

66. (Previously presented) The method of claim 62, wherein said anti- $\text{TNF}\alpha$ F(ab')_2 neutralizing antibody fragments are administered within 24 hours following a corneal transplant in said patient.

67. (Previously presented) The method of claim 66, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered within 2 hours following a corneal transplant in said patient.

68. (Previously presented) The method of claim 67, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered within 30 minutes following a corneal transplant in said patient.

69. (Previously presented) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered at least 3 times a day for about 8 weeks.

70. (Previously presented) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered about every 10 to 12 hours for about 8 weeks.

71. (Previously presented) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in an ophthalmic suspension or ointment.

72. (Previously presented) The method of claim 71, wherein said ophthalmic suspension or ointment comprises about 20 mg/ml to about 30 mg/ml of said anti-TNF α F(ab')₂ neutralizing antibody fragments.

73-75. (Cancelled)

76. (Previously presented) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in a dermatologically acceptable gel vehicle comprising about 0.01% to about 50% by weight of anti-TNF α F(ab')₂ neutralizing antibody fragments.

77. (Previously presented) The method of claim 62, wherein said anti-TNF α F(ab')₂ neutralizing antibody fragments are administered in a dermatologically acceptable semi-solid vehicle comprising about 0.01% to about 50% by weight of anti-TNF α F(ab')₂ neutralizing antibody fragments.